<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2912246500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEIZET 25 mg Chewable/Dispersible Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMOTRIGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable/dispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />Seizet belongs to a group of medicines called anti-epileptics. It is used to treat two conditions<br />- epilepsy and bipolar disorder.</p><p><br />Therapeutic indications:<br />Seizet treats epilepsy by blocking the signals in the brain that trigger epileptic seizures (fits)<br />&bull; For adults and children aged 13 years and over, Seizet can be used on its own or with other medicines, to treat epilepsy. Seizet can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome.<br />&bull; For children aged between 2 and 12 years, Seizet can be used with other medicines, to treat those conditions. It can be used on its own to treat a type of epilepsy called typical absence seizures.<br />Seizet also treats bipolar disorder<br />People with bipolar disorder (sometimes called manic depression) have extreme mood swings, with periods of mania (excitement or euphoria) alternating with periods of depression (deep sadness or despair). For adults aged 18 years and over, Seizet can be used on its own or with other medicines, to prevent the periods of depression that occur in bipolar disorder. It is not yet known how Seizet works in the brain to have this effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Seizet</strong><br />If you are allergic (hypersensitive) to lamotrigine or any of the other ingredients of this medicine.<br />If this applies to you tell your doctor and don&rsquo;t take Seizet.</p><p><br /><strong>b. Take special care with Seizet</strong><br />Talk to your doctor or pharmacist before taking Seizet:<br />&bull;If you have any kidney problems<br />&bull;If you have ever developed a rash after taking lamotrigine or other medicines for bipolar disorder or epilepsy<br />&bull;If you have ever developed meningitis after taking lamotrigine<br />&bull;If you are already taking medicine that contains lamotrigine.<br />If any of these applies to you tell your doctor, who may decide to lower the dose or that Seizet is not suitable for you.</p><p>Important information about potentially life-threatening reactions<br />A small number of people taking Seizet get an allergic reaction or potentially life-threatening skin reaction, which may develop into more serious problems if they are not treated. These can include Stevens&ndash;Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). You need to know the symptoms to look out for while you are taking Seizet.<br />Thoughts of harming yourself or suicide Anti-epileptic medicines are used to treat several conditions, including epilepsy and bipolar<br />disorder. People with bipolar disorder can sometimes have thoughts of harming themselves or committing suicide. If you have bipolar disorder, you may be more likely to think like this:<br />&bull;When you first start treatment<br />&bull;If you have previously had thoughts about harming yourself or about suicide<br />&bull;If you are under 25 years old.<br />If you have distressing thoughts or experiences, or if you notice that you feel worse or develop new symptoms while you&rsquo;re taking Seizet:<br />See a doctor as soon as possible or go to the nearest hospital for help.</p><p>You may find it helpful to tell a family member, caregiver or close friend that you can become depressed or have significant changes in mood, and ask them to read this leaflet. You might ask them to tell you if they are worried about your depression or other changes in your be-haviour.</p><p>A small number of people being treated with anti-epileptics such as Seizet have also had<br />thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.<br />If you&rsquo;re taking Seizet for epilepsy<br />The seizures in some types of epilepsy may occasionally become worse or happen more often while you&rsquo;re taking Seizet. Some patients may experience severe seizures, which may cause serious health problems. If your seizures happen more often or if you experience a severe seizure while you&rsquo;re taking Seizet:<br />See a doctor as soon as possible.<br />Seizet should not be given to people aged under 18 years to treat bipolar disorder. Medicines to treat depression and other mental health problems increase the risk of suicidal thoughts and behaviour in children and adolescents aged under 18 years.</p><p><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including herbal medicines or other medicines bought without a prescription.<br />Your doctor needs to know if you are taking other medicines to treat epilepsy or mental health problems. This is to make sure you take the correct dose of Seizet. These medicines include:<br />&bull;Oxcarbazepine, felbamate, gabapentin, levetiracetam, pregabalin, topiramate or zonisamide, used to treat epilepsy<br />&bull;Lithium, olanzapine or aripiprazole used to treat mental health problems<br />&bull;Bupropion, used to treat mental health problems or to stop smoking<br />Tell your doctor if you are taking any of these.</p><p>Some medicines interact with Seizet or make it more likely that people will have side effects. These include:<br />&bull;Valproate, used to treat epilepsy and mental health problems<br />&bull;Carbamazepine, used to treat epilepsy and mental health problems<br />&bull;Phenytoin, primidone or phenobarbitone, used to treat epilepsy<br />&bull;Risperidone, used to treat mental health problems<br />&bull;Rifampicin, which is an antibiotic<br />&bull;Medicines used to treat Human Immunodeficiency Virus (HIV) infection (a combination of lopinavir and ritonavir or atazanavir and ritonavir)<br />&bull;Hormonal contraceptives, such as the Pill.<br />Tell your doctor if you are taking any of these or if you start or stop taking any.</p><p>Hormonal contraceptives (such as the Pill) can affect the way Seizet works<br />Your doctor may recommend that you use a particular type of hormonal contraceptive or another method of contraception, such as condoms, a cap or coil. If you are using a hormonal contraceptive like the Pill, your doctor may take samples of your blood to check the level of Seizet. If you are using a hormonal contraceptive or if you plan to start using one:<br />Talk to your doctor, who will discuss suitable methods of contraception with you.</p><p>Seizet can also affect the way hormonal contraceptives work, although it&rsquo;s unlikely to make them less effective. If you are using a hormonal contraceptive and you notice any changes in your menstrual pattern, such as breakthrough bleeding or spotting between periods:<br />Tell your doctor. These may be signs that Seizet is affecting the way your contraceptive is working.</p><p><strong>d. Taking Seizet with food and drink</strong><br />It can be taken with or without food.</p><p><strong>e. Pregnancy and breast-feeding</strong><br />Pregnancy:<br />If you are pregnant, think you may be pregnant or are planning to have a baby ask your doctor or pharmacist for advice before taking this medicine.<br />You should not stop treatment without discussing this with your doctor. This is particularly important if you have epilepsy.<br />Pregnancy may alter the effectiveness of Seizet, so you may need blood tests and your dose of Seizet may be adjusted.<br />There may be a small increased risk of birth defects, including a cleft lip or cleft palate, if Seizet is taken during the first 3 months of pregnancy.<br />Your doctor may advise you to take extra folic acid if you&rsquo;re planning to become pregnant and while you&rsquo;re pregnant.</p><p>Breast-feeding:<br />If you are breast-feeding or planning to breast-feed ask your doctor or pharmacist for advice before taking this medicine. The active ingredient of Seizet passes into breast milk and may affect your baby. Your doctor will discuss the risks and benefits of breast-feeding while you&rsquo;re taking Seizet and will check your baby from time to time if you decide to breast-feed.</p><p><strong>f. Driving and using machines</strong><br />Seizet can cause dizziness and double vision.<br />Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.<br />If you have epilepsy, talk to your doctor about driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist</strong> has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>How much Seizet to take </strong></p><p>It may take a while to find the best dose of Seizet for you. The dose you take will depend on:</p><p>&bull; Your age<br />&bull; Whether you are taking Seizet with other medicines<br />&bull; Whether you have any kidney or liver problems.<br />Your doctor will prescribe a low dose to start and gradually increase the dose over a few weeksuntil you reach a dose that works for you (called the effective dose). Never take more Seizet than your doctor tells you to.</p><p>The usual effective dose of Seizet for adults and children aged 13 years or over is between 100 mg and 400 mg each day.<br />For children aged 2 to 12 years, the effective dose depends on their body weight - usually, it&rsquo;s between 1 mg and 15 mg for each kilogram of the child&rsquo;s weight, up to a maximum maintenance dose of 200 mg daily.</p><p>Seizet is not recommended for children aged under 2 years.</p><p><strong>How to take your dose of Seizet</strong><br />Take your dose of Seizet once or twice a day, as your doctor advises. It can be taken with or without food.<br />Always take the full dose that your doctor has prescribed. Never take only part of a tablet. Your doctor may also advise you to start or stop taking other medicines, depending on what condition you&rsquo;re being treated for and the way you respond to treatment.</p><p>Seizet chewable/dispersible tablets can either be swallowed whole with a little water, chewed or mixed with water to make a liquid medicine.<br />To chew the tablet:<br />You may need to drink a little water at the same time to help the tablet dissolve in the mouth.<br />Then drink some more water to make sure all the medicine has been swallowed.<br />To make a liquid medicine:<br />&bull; Put the tablet in a glass with at least enough water to cover the whole tablet.<br />&bull; Either stir to dissolve or wait until the tablet is fully dissolved.<br />&bull; Drink all the liquid.<br />&bull; Add a little more water to the glass and drink that, to make sure no medicine is left in the glass.</p><p><strong>a. If you take more Seizet than you should</strong><br />Contact a doctor or nearest hospital emergency department immediately. If possible, show them the Seizet packet.<br />If you take too much Seizet you may be more likely to have serious side effects which may be fatal.<br />Someone who has taken too much Seizet may have any of these symptoms:<br />&bull;Rapid, uncontrollable eye movements (nystagmus)<br />&bull;Clumsiness and lack of co-ordination, affecting their balance (ataxia)<br />&bull;Heart rhythm changes (detected usually on ECG)<br />&bull;Loss of consciousness, fits (convulsions) or coma.</p><p><strong>b. If you forget to take Seizet</strong><br />Don&rsquo;t take extra tablets to make up for a missed dose. Just take your next dose at the usual time.</p><p>In case you forget to take multiple doses of Seizet<br />Ask your doctor for advice on how to start taking it again. It&rsquo;s important that you do this.</p><p><strong>If you stop taking Seizet</strong><br />Don&rsquo;t stop taking Seizet without advice<br />Seizet must be taken for as long as your doctor recommends. Don&rsquo;t stop unless your doctor advises you to.<br />To stop taking Seizet, it is important that the dose is reduced gradually, over about 2 weeks. If you suddenly stop taking Seizet, your epilepsy may come back or get worse.</p><p><strong>If you&rsquo;re taking Seizet for bipolar disorder</strong><br />Seizet may take some time to work, so you are unlikely to feel better straight away. If you stop taking Seizet, your dose will not need to be reduced gradually. But you should still talk to your doctor first, if you want to stop taking Seizet.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, but not everyone gets them.<br />Potentially life-threatening reactions: get a doctor&rsquo;s help straight away A small number of people taking Seizet get an allergic reaction or potentially life-threatening skin reaction, which may develop into more serious problems if they are not treated.<br />These symptoms are more likely to happen during the first few months of treatment with Seizet, especially if the starting dose is too high or if the dose is increased too quickly or if Seizet is taken with another medicine called valproate. Some of the symptoms are more common in children, so parents should be especially careful to watch out for them.</p><p>Symptoms of these reactions include:<br />&bull;Skin rashes or redness, which may develop into life-threatening skin reactions including widespread rash with blisters and peeling skin, particularly occurring around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), extensive peeling of the skin (more than 30% of the body surface - toxic epidermal necrolysis) or extended rashes with liver, blood and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS hypersensitivity syndrome)<br />&bull;Ulcers in the mouth, throat, nose or genitals<br />&bull;A sore mouth or red or swollen eyes (conjunctivitis)<br />&bull;A high temperature (fever), flu-like symptoms or drowsiness</p><p>&bull;Swelling around your face or swollen glands in your neck, armpit or groin<br />&bull;Unexpected bleeding or bruising, or the fingers turning blue<br />&bull;A sore throat or more infections (such as colds) than usual<br />&bull;Increased levels of liver enzymes seen in blood tests<br />&bull;An increase in a type of white blood cell (eosinophils)<br />&bull;Enlarged lymph nodes<br />&bull;Involvement of the organs of the body including liver and kidneys.<br />In many cases, these symptoms will be signs of less serious side effects but you must be aware that they are potentially life-threatening and can develop into more serious problems, such as organ failure, if they are not treated. If you notice any of these symptoms:<br />Contact a doctor immediately. Your doctor may decide to carry out tests on your liver, kidneys or blood and may tell you to stop taking Seizet. In case you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis your doctor will tell you that you must never<br />use lamotrigine again.</p><p><strong>Very common side effects &ldquo;These may affect more than 1 in 10 people&rdquo;:</strong><br />&bull;Headache<br />&bull;Skin rash.</p><p><br /><strong>Common side effects &ldquo;These may affect up to 1 in 10 people&rdquo;:</strong><br />&bull;Aggression or irritability<br />&bull;Feeling sleepy or drowsy<br />&bull;Feeling dizzy<br />&bull;Shaking or tremors<br />&bull;Difficulty in sleeping (insomnia)<br />&bull;Feeling agitated<br />&bull;Diarrhoea<br />&bull;Dry mouth<br />&bull;Feeling sick (nausea) or being sick (vomiting)<br />&bull;Feeling tired<br />&bull;Pain in your back or joints, or elsewhere.</p><p><strong>Uncommon side effects &ldquo;These may affect up to 1 in 100 people&rdquo;:</strong><br />&bull;Clumsiness and lack of co-ordination (ataxia)<br />&bull;Double vision or blurred vision<br />&bull;Unusual hair loss or thinning (alopecia).</p><p><strong>Rare side effects &ldquo;These may affect up to 1 in 1,000 people&rdquo;:</strong><br />&bull;A life-threatening skin reaction (Stevens-Johnson syndrome):<br />&bull;A group of symptoms together including: fever, nausea, vomiting, headache, stiff neck and extreme sensitivity to bright light. This may be caused by an inflammation of the membranes that cover the brain and spinal cord (meningitis). These symptoms usually disappear once treatment is stopped however if the symptoms continue or get worse contact your doctor<br />&bull;Rapid, uncontrollable eye movements (nystagmus)<br />&bull;Itchy eyes, with discharge and crusty eyelids (conjunctivitis).</p><p><br /><strong>Very rare side effects These may affect up to 1 in 10,000 people:</strong><br />&bull;A life-threatening skin reaction (toxic epidermal necrolysis)<br />&bull;Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)<br />&bull;A high temperature (fever)<br />&bull;Swelling around the face (oedema) or swollen glands in the neck, armpit or groin (lymphadenopathy)<br />&bull;changes in liver function, which will show up in blood tests or liver failure<br />&bull;S serious disorder of blood clotting, which can cause unexpected bleeding or bruising (disseminated intravascular coagulation)<br />&bull;Changes which may show up in blood tests - including reduced numbers of red blood cells (anaemia), reduced numbers of white blood cells (leucopenia, neutropenia, agranulocytosis), reduced numbers of platelets (thrombocytopenia), reduced numbers of all these types of cell (pancytopenia) and a disorder of the bone marrow called aplastic anaemia<br />&bull;Hallucinations (&lsquo;seeing&rsquo; or &lsquo;hearing&rsquo; things that aren&rsquo;t really there)<br />&bull;Confusion<br />&bull;Feeling &lsquo;wobbly&rsquo; or unsteady when you move about<br />&bull;Uncontrollable body movements (tics), uncontrollable muscle spasms affecting the eyes, head and torso (choreoathetosis) or other unusual body movements such as jerking, shaking or stiffness<br />&bull;In people who already have epilepsy, seizures happening more often<br />&bull;In people who already have Parkinson&rsquo;s disease, worsening of the symptoms.<br />&bull;Lupus-like reaction (symptoms may include: back or joint pain which sometimes may be accompanied by fever and/or general ill health).</p><p><strong>Other side effects</strong><br />Other side effects have occurred in a small number of people but their exact frequency is unknown:<br />&bull;There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis or take steroids<br />&bull;Nightmares<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p>&nbsp;</p><p><strong>&nbsp;To report any side effect(s):</strong><br />&bull;Saudi Arabia:<br />National Pharmacovigilance and Drug Safety Centre (NPC) :<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa</p><p>&bull;Other GCC States<br />-Please contact the relevant competent authority.</p><p>. Council of Arab Health Ministers<br />This is a medicament<br />&middot; Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.<br />&middot; Follow strictly the doctor&rsaquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.<br />&middot; The doctor and the pharmacist are experts in medicine, its benefits and risks.<br />&middot; Do not by yourself interrupt the period of treatment prescribed for you.<br />&middot; Do not repeat the same prescription without consulting your doctor.<br />&middot; Keep medicament out of the reach of children.</p><p>COUNCIL OF ARAB HEALTH MINISTERS<br />UNION OF ARAB PHARMACIST<br />. This patient information leaflet is approved by the Saudi Food and Drug Authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-Keep out of the reach and sight of children.<br />-Do not store above 30&deg;C.<br />-Do not use Seizet after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />-Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose&nbsp;of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: Lamotrigine.<br />Seizet 25mg Dispersible/Chewable Tablets: Each Dispersible/Chewable tablet contains Lamotrigine 25 mg.<br />Seizet 50mg Dispersible/Chewable Tablets: Each Dispersible/Chewable tablet contains Lamotrigine 50mg.<br />Seizet 100mg Dispersible/Chewable Tablets: Each Dispersible/Chewable tablet contains Lamotrigine 100 mg.</p><p>The other ingredients are: Calcium Carbonate, Povidone, Sodium Starch Glycolate, Aluminum Magnesium Silicate, Sodium saccharine, Low-substituted hydroxypropyl cellulose, Black current flavor and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dispersible/Chewable tablets.
Physical Description:
-Seizet 25mg Dispersible/Chewable Tablets: White rounded square dispersible tablet flat embossed with D10 on one side, multifaceted plain on the other.
-Seizet 50mg Dispersible/Chewable Tablets: White round tablet embossed with T22 on one side plane on the other.
-Seizet 100mg Dispersible/Chewable Tablets: White square elliptical uncoated tablet plane embossed with E45 on one side, multifaceted on the other.

Seizet Dispersible/Chewable Tablets: are packed in PVC/PVDC, Aluminum blister then packed in cardboard cartons with a multifold leaflet.

Pack size: 30 Dispersible/Chewable Tablets; (10 Dispersible/Chewable Tablets /blister, 3 blisters/ pack).
Hospital packs are also available
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi</p><p>Riyadh, Kingdome Saudi Arabia.<br />info-ksa@mspharma.com</p><p><br />Manufacturer by:<br />United Pharmaceutical Mfg. Co. Ltd. - Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 Feb/2020; version number: SPM190319
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سيزيت ينتمي إلى مجموعة من الأدوية تسمى مضادات الصرع. يتم استخدامه لعلاج حالتين - الصرع والاضطراب ثنائي القطب</p><p>:الاستعمالات العلاجية</p><p>يعالج سيزيت&nbsp; الصرع عن طريق منع الإشارات في الدماغ التي تؤدي إلى نوبات الصرع (التشنجات)</p><p>بالنسبة للبالغين والأطفال بعمر 13 سنة فأكثر، يمكن استخدام سيزيت لوحده أو مع أدوية أخرى، لعلاج الصرع. ويمكن استخدام سيزيت&nbsp; أيضا مع أدوية أخرى لعلاج التشنجات التي تحدث مع حالة تسمى متلازمة لينوكس-غاستوت</p><p>&nbsp;بالنسبة للأطفال الذين تتراوح أعمارهم بين سنتين و 12 سنة، يمكن استخدام سيزيت مع أدوية أخرى لعلاج هذه الحالات. ويمكن استخدامه لوحده لعلاج نوع من الصرع يسمى نوبات غياب نموذجي</p><p>كما يعالج سيزيت&nbsp; الاضطراب ثنائي القطب</p><p>الأشخاص الذين يعانون من اضطراب ثنائي القطب (ويسمى أحيانا الاكتئاب الهوسي) لديهم تقلبات مزاجية شديدة، مع فترات من الهوس (الإثارة أو النشوة) بالتناوب مع فترات اكتئاب (الحزن العميق أو اليأس). للبالغين الذين تتراوح أعمارهم بين 18 سنة وما فوق، سيزيت&nbsp; يمكن استخدامه لوحده أو مع أدوية أخرى، لمنع فترات الاكتئاب التي تحدث في اضطراب ثنائي القطب. لم يعرف بعد كيف يعمل سيزيت&nbsp; في الدماغ لإحداث هذا التأثير</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;أ. موانع استعمال سيزيت&nbsp;</strong></p><p>إذا كنت تعاني من حساسية (فرط الحساسية) لمادة لاموتريجين أو لأي من المكونات الأخرى لهذا الدواء</p><p>إذا كان هذا ينطبق عليك أخبر طبيبك، ولا تأخذ سيزيت</p><p>&nbsp;</p><p><strong>ب. الاحتياطات عند استعمال سيزيت&nbsp;</strong></p><p>تحدث مع طبيبك أو الصيدلي قبل أخذ سيزيت</p><p>إذا كان لديك أي مشاكل في الكلى</p><p>&nbsp;إذا حدث لك في أي وقت سابق طفح جلدي بعد تناول لاموتريجين أو أي أدوية أخرى لعلاج الاضطراب ثنائي القطب أو الصرع</p><p>إذا حدث لك في أي وقت سابق التهاب السحايا بعد أخذ لاموتريجين</p><p>إذا كنت تتناول دواء يحتوي على لاموترجين</p><p>يجب تخبر طبيبك إذا كان أي من هذه ينطبق عليك، الذي قد يقرر خفض الجرعة أو يقرر أن سيزيت&nbsp; ليس مناسب لك</p><p>&nbsp;</p><p>معلومات هامة حول ردود الفعل المحتملة التي تهدد الحياة</p><p>هناك عدد قليل من الناس الذين يتناولون سيزيت&nbsp; يحدث لديهم رد فعل تحسسي أو رد فعل جلدي قد يهدد الحياة، والذي قد يتطور إلى مشاكل أكثر خطورة إذا لم يتم علاجه. يمكن أن تشمل هذه على متلازمة ستيفنز جونسون، انحلال البشرة السام وردود الفعل المرتبطة باستخدام الدواء مع فرط الحمضات والأعراض الجهازية. تحتاج إلى معرفة الأعراض للبحث عنها عند تناولك سيزيت&nbsp;</p><p>أفكار لتضر نفسك أو الانتحار</p><p>تستخدم الأدوية المضادة للصرع لعلاج العديد من الحالات، بما فيها الصرع والاضطراب ثنائي القطب. الناس الذين يعانون من اضطراب ثنائي القطب يمكن أن يكون لديهم أحيانا أفكار عن إيذاء أنفسهم أو الانتحار. إذا كان لديك اضطراب ثنائي القطب، قد تكون أكثر عرضة للتفكير في مثل هذا</p><p>عند بدء العلاج</p><p>إذا كان لديك أفكار في السابق حول إيذاء نفسك أو عن الانتحار</p><p>إذا كان عمرك أقل من 25 سنة</p><p>إذا كان لديك أفكار أو تجارب مؤلمة، أو إذا لاحظت أنك تشعر بشكل أسوأ أو تطور لديك أعراض جديدة أثناء أخذ سيزيت</p><p>راجع الطبيب في أقرب وقت ممكن أو اذهب إلى أقرب مستشفى للحصول على المساعدة</p><p>قد تجد أنه من المفيد أن تخبر أحد أفراد العائلة أو مقدم الرعاية أو صديق مقرب بأنك قد تصبح مكتئبا أو لديك تغييرات كبيرة في المزاج، واطلب منهم قراءة هذه النشرة. قد تطلب منهم أن يخبروك إذا كانوا قلقين بشأن اكتئابك أو أي تغييرات أخرى في سلوكك</p><p>هناك عدد قليل من الناس الذين يعالجون بمضادات الصرع مثل سيزيت&nbsp; لديهم أيضا أفكار من إيذاء أو قتل أنفسهم. إذا كان لديك في أي وقت مثل هذه الأفكار، اتصل على الفور بالطبيب</p><p>إذا كنت تأخذ سيزيت&nbsp; للصرع</p><p>قد تصبح التشنجات في بعض أنواع الصرع في بعض الأحيان أسوأ أو تحدث التشنجات في كثير من الأحيان عند أخذ سيزيت . قد يواجه بعض المرضى نوبات شديدة، مما قد يسبب مشاكل صحية خطيرة. إذا حدثت لديك التشنجات في كثير من الأحيان أو إذا كنت تواجه نوبة شديدة عند أخذ سيزيت</p><p>راجع الطبيب في أقرب وقت ممكن</p><p>يجب عدم إعطاء سيزيت&nbsp; للأشخاص الذين تقل أعمارهم عن 18 عاما لعلاج الاضطراب ثنائي القطب. تزيد الأدوية لعلاج الاكتئاب ومشاكل الصحة العقلية الأخرى من خطر الأفكار الانتحارية والانتحار لدى الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما</p><p><strong>ج. التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تأخذ أي أدوية أخرى بما في ذلك الأدوية العشبية أو الأدوية الأخرى التي تؤخذ دون وصفة طبية</p><p>يجب أن يعرف طبيبك ما إذا كنت تتناول أدوية أخرى لعلاج الصرع أو لعلاج مشاكل الصحة العقلية. هذا هو للتأكد من أنك تأخذ الجرعة الصحيحة من سيزيت</p><p>: وتشمل هذه الأدوية</p><p>&nbsp;أوكسكاربازيبين، فيلبامات، غابابنتين، ليفيتيراسيتام، بريغابالين، توبيراميت أو زونيساميد، وتستخدم لعلاج الصرع</p><p>ليثيوم، أولانزابين أو أريبيبرازول تستخدم لعلاج مشاكل الصحة العقلية</p><p>&nbsp;بوبروبيون، يستخدم لعلاج مشاكل الصحة النفسية أو التوقف عن التدخين</p><p>أخبر طبيبك إذا كنت تأخذ أي من هذه</p><p>:بعض الأدوية تتداخل مع سيزيت&nbsp; أو تجعل من المرجح أن يكون لها آثار جانبية في الناس. وتشمل هذه</p><p>&nbsp;فالبروات، وتستخدم لعلاج الصرع ومشاكل الصحة العقلية</p><p>&nbsp;كاربامازيبين، وتستخدم لعلاج الصرع ومشاكل الصحة العقلية</p><p>&nbsp;الفينيتوين، بريميدون أو الفينوباربيتون، وتستخدم لعلاج الصرع</p><p>ريسبيريدون، وتستخدم لعلاج مشاكل الصحة العقلية</p><p>&nbsp;ريفامبيسين، وهو مضاد حيوي</p><p>&nbsp;الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية (مزيج من لوبينافير و ريتونافير أو أتازانافير و ريتونافير)</p><p>وسائل منع الحمل الهرمونية، مثل حبوب منع الحمل</p><p>أخبر طبيبك إذا كنت تأخذ أي من هذه أو إذا كنت بدأت أو توقفت عن تناول أي منها</p><p>يمكن أن تؤثر وسائل منع الحمل الهرمونية (مثل حبوب منع الحمل) على طريقة عمل سيزيت&nbsp;</p><p>قد يوصي طبيبك باستخدام نوع معين من وسائل منع الحمل الهرمونية أو طريقة أخرى لمنع الحمل، مثل الواقي الذكري أو غطاء أو لفائف. إذا كنت تستخدم وسائل منع حمل هرمونية مثل حبوب منع الحمل، قد يأخذ طبيبك عينات من الدم الخاص بك للتحقق من مستوى سيزيت . إذا كنت تستخدم وسائل منع حمل هرمونية أو إذا كنت تخططين لبدء استخدام واحد</p><p>تحدثي مع طبيبك، الذي سيناقش معك وسائل منع الحمل المناسبة</p><p>يمكن أن تؤثر سيزيت&nbsp; أيضا على طريقة عمل وسائل منع الحمل الهرمونية، على الرغم من أنه من غير المرجح أن تجعلها أقل فعالية. إذا كنت تستخدم وسائل منع حمل هرمونية ولاحظت أي تغييرات في نمط الطمث الخاص بك، مثل نزيف غير متوقع أو تنقيط بين الدورات الشهرية</p><p>أخبر طبيبك. قد تكون هذه علامات على أن سيزيت&nbsp; يؤثر على طريقة عمل وسائل منع الحمل</p><p>&nbsp;</p><p><strong>د. تناول سيزيت&nbsp; مع الطعام والشراب</strong></p><p>يمكن أن يؤخذ مع أو دون تناول الطعام</p><p>&nbsp;</p><p><strong>هـ. الحمل والرضاعة</strong></p><p>:الحمل</p><p>إذا كنت حاملا، تفكرين بأنك قد تكون حاملا أو تخططين لحدوث الحمل يجب أن تطلبي المشورة من طبيبك أو الصيدلي قبل تناول هذا الدواء</p><p>يجب أن لا تتوقفي عن العلاج دون مناقشة هذا مع طبيبك. هذا مهم بشكل خاص إذا كنت تعانين من الصرع</p><p>قد يغير الحمل من فعالية سيزيت ، لذلك قد تحتاج إلى إجراء اختبارات للدم و يمكن تعديل جرعة سيزيت</p><p>قد يكون هناك خطر زيادة طفيفة لحدوث عيوب خلقية، بما في ذلك الشفة المشقوقة أو الحنك المشقوق، إذا تم أخذ سيزيت&nbsp; خلال الأشهر الثلاثة الأولى من الحمل</p><p>قد ينصحك الطبيب بتناول حمض الفوليك بشكل إضافي إذا كنت تخططين لحدوث الحمل أو خلال فترة الحمل</p><p>&nbsp;</p><p>الرضاعة الطبيعية</p><p>إذا كنت ترضعين أو تخططين للرضاعة الطبيعية استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. ينتقل العنصر النشط من سيزيت&nbsp; إلى حليب الثدي وقد يؤثر على طفلك. سوف يناقش طبيبك مخاطر وفوائد الرضاعة الطبيعية أثناء تناولك لسيزيت&nbsp; وسوف يفحص طفلك من وقت لآخر إذا قررت إكمال الرضاعة الطبيعية</p><p>&nbsp;</p><p><strong>و. القيادة واستعمال الآلات</strong></p><p>يمكن أن يسبب سيزيت&nbsp; في حدوث الدوخة والرؤية المزدوجة</p><p>لا تقد أو تستخدم الآلات إلا إذا كنت متأكدا من أنك لا تتأثر بتاوله</p><p>إذا كنت مصابا بالصرع، تحدث مع طبيبك حول القيادة واستخدام الالات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول هذا الدواء تماما كما قال لك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد</p><p>كم ستأخذ من سيزيت&nbsp;</p><p>قد يستغرق بعض الوقت للوصول إلى أفضل جرعة من سيزيت بالنسبة لك. تعتمد الجرعة التي تتناولها على</p><p>عمرك-</p><p>ما إذا كنت تتناول سيزيت&nbsp; مع أدوية أخرى-</p><p>ما إذا كان لديك أي مشاكل في الكلى أو الكبد-</p><p>سوف يصف طبيبك جرعة منخفضة للبدء وبعدها يزيد الجرعة تدريجيا على مدى بضعة أسابيع للوصول للجرعة التي تناسبك (تسمى الجرعة الفعالة). لا تأخذ سيزيت&nbsp; أكثر مما أخبرك به طبيبك</p><p>الجرعة الفعالة الاعتيادية من سيزيت&nbsp; للبالغين والأطفال الذين تتراوح أعمارهم بين 13 سنة أو أكثر ما بين 100 ملغم و 400 ملغم كل يوم</p><p>بالنسبة للأطفال الذين تتراوح أعمارهم بين سنتين و 12 سنة، تعتمد الجرعة الفعالة على وزن الجسم - وعادة ما تكون بين 1 ملغم و 15 ملغم لكل كيلوغرام من وزن الطفل، تبلغ الجرعة الاستمرارية القصوى 200 ملغم يوميا</p><p>لا ينصح باستخدام سيزيت&nbsp; للأطفال الذين تقل أعمارهم عن سنتين</p><p>&nbsp;</p><p>كيفية أخذ جرعة من سيزيت</p><p>تأخذ جرعة سيزيت&nbsp; مرة واحدة أو مرتين في اليوم، كما نصح الطبيب. ويمكن أن تؤخذ بغذ النظر عن تناول الطعام</p><p>دائما خذ الجرعة كاملة والتي وصفها لك الطبيب. لا تأخذ جزء من القرص</p><p>قد ينصحك الطبيب أيضا ببدء أو التوقف عن تناول أدوية أخرى، حسب الحالة التي يتم علاجك فيها والطريقة التي تستجيب بها للعلاج</p><p>يمكن بلع أقراص سيزيت&nbsp; القابلة للتفتت / القابلة للمضغ بالكامل مع قليل من الماء أو مضغها أو خلطها بالماء للحصول على دواء سائل</p><p>&nbsp;</p><p>لمضغ الأقراص</p><p>قد تحتاج إلى شرب القليل من الماء في نفس الوقت لمساعدة القرص على الذوبان في الفم. ثم اشرب بعض الماء أكثر للتأكد من أن كل الدواء قد تم بلعه</p><p>&nbsp;</p><p>للحصول على دواء سائل</p><p>ضع القرص في كوب مع كمية من الماء كافیة لتغطیة القرص بالكامل</p><p>إما قم بالتحريك لتسريع الذوبان أو انتظر حتى يذوب القرص بالكامل</p><p>اشرب كامل السائل</p><p>أضف القليل من الماء إلى الكأس واشربه، للتأكد من عدم ترك أي دواء في الكأس</p><p>&nbsp;</p><p><strong>أ. إذا تناولت سيزيت&nbsp; أكثر مما يجب</strong></p><p>اتصل بالطبيب أو أقرب قسم للطوارئ في المستشفى على الفور. إذا كان ذلك ممكنا، أظهر لهم علبة سيزيت</p><p>إذا أخذت الكثير من سيزيت&nbsp; ، قد يكون من المرجح أن يكون لها آثار جانبية خطيرة والتي قد تكون قاتلة</p><p>قد تناول شخص الكثير من سيزيت&nbsp; ، فقد يتعرض لأي من هذه الأعراض</p><p>حركات سريعة في العين، والتي لا يمكن السيطرة عليها (رأرأة)</p><p>التباين وعدم التنسيق، مما يؤثر على التوازن (رنح)</p><p>تغيرات في إيقاع القلب (الكشف عادة من تخطيط القلب)</p><p>&nbsp;فقدان الوعي، نوبات (التشنجات) أو غيبوبة</p><p>&nbsp;</p><p><strong>ب. إذا نسيت تناول سيزيت&nbsp;</strong></p><p>لا تأخذ أقراص إضافية لتعويض الجرعة المنسية. فقط خذ الجرعة التالية في الوقت المعتاد</p><p>في حال قد نسيت أخذ جرعات متعددة من سيزيت ، استشر طبيبك بشأن كيفية بدء تناوله مرة أخرى. من المهم أن تقوم بذلك</p><p>&nbsp;</p><p><strong>ج. اذا توقفت عن تناول سيزيت&nbsp;</strong></p><p>لا تتوقف عن أخذ سيزيت&nbsp; دون استشارة طبية</p><p>يجب أن تؤخذ سيزيت&nbsp; طالما أوصاك الطبيب بذلك. لا تتوقف ما لم ينصحك الطبيب</p><p>لإيقاف أخذ سيزيت ، من المهم أن يتم تخفيض الجرعة تدريجيا، على مدى حوالي أسبوعين. إذا توقفت فجأة عن تناول سيزيت ، قد يعود الصرع أو يزداد سوءا</p><p>&nbsp;</p><p>إذا كنت تأخذ سيزيت&nbsp; للاضطراب ثنائي القطب</p><p>قد يحتاج سيزيت&nbsp; لبعض الوقت للعمل، لذلك من غير المرجح أن يشعر المريض بتحسن على الفور. إذا توقفت عن تناول سيزيت ، لن تحتاج إلى خفض الجرعة تدريجيا. ولكن يجب عليك التحدث مع طبيبك أولا، إذا كنت تريد التوقف عن تناول سيزيت</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال في جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، ولكن ليس كل شخص يصاب بهاا</p><p>ردود الفعل المحتملة التي تهدد الحياة: أطلب مساعدة الطبيب على الفور</p><p>هناك عدد قليل من الناس الذين يتناولون سيزيت&nbsp; يصابون برد فعل تحسسي أو رد فعل جلدي يحتمل أن يهدد الحياة، والذي قد يتطور إلى مشاكل أكثر خطورة إذا لم يتم علاجه</p><p>من المرجح أن تحدث هذه الأعراض خلال الأشهر القليلة الأولى من العالج باستخدام سيزيت ، خاصة إذا كانت جرعة البدء مرتفعة جدا أو إذا زادت الجرعة بسرعة كبيرة أو إذا أخذت سيزيت&nbsp; مع دواء آخر يسمى فالبروات. بعض الأعراض أكثر شيوعا في الأطفال، لذلك يجب على الآباء أن يكونو حريصين بشكل خاص على مراقبتهم</p><p>&nbsp;:تشمل أعراض هذه التفاعلات على ما يلي</p><p>الطفح الجلدي أو احمرار الجلد، والذي قد يتطور إلى ردود فعل جلدية تهدد الحياة بما في ذلك الطفح الجلدي الواسع مع بثور وتقشير الجلد، وخاصة تحدث حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)، وتقشير واسعة من الجلد (أكثر من 30٪ من سطح الجسم &ndash; انحلال البشرة السام) أو الطفح الجلدي الواسع مع مشاركة الكبد والدم وغيرها من أعضاء الجسم (وردود الفعل المرتبطة باستخدام الدواء مع فرط الحمضات والأعراض الجهازية التي تعرف أيضا فرط الحساسية)</p><p>قرحة في الفم، الحلق، الأنف أو الأعضاء التناسلية</p><p>&nbsp;تقرح في الفم أو أحمرار أو تورم في العينين (التهاب الملتحمة)</p><p>&nbsp;ارتفاع درجة الحرارة(حمى)، أعراض شبيهة بالانفلونزا أو النعاس</p><p>تورم حول وجهك أو تورم الغدد في عنقك أو إبطتك أو فخذك</p><p>نزف أو كدمات غير متوقعة، أو تحول الأصابع إلى اللون الأزرق</p><p>التهاب في الحلق أو انتانات أكثر (مثل نزلات البرد) من المعتاد</p><p>زيادة مستويات إنزيمات الكبد في فحوص الدم</p><p>زيادة في نوع من خلايا الدم البيضاء (الحمضات)</p><p>&nbsp;تضخم الغدد الليمفاوية</p><p>&nbsp;يشمل تأثيره أجهزة الجسم بما في ذلك الكبد والكلى</p><p>في كثير من الحالات، تكون هذه الأعراض علامات تدل على آثار جانبية أقل خطورة ولكن يجب أن تكون على علم بأنها من المحتمل أن تكون مهددة للحياة ويمكن أن&nbsp; تتطور إلى مشاكل أكثر خطورة، مثل فشل العضو، إذا لم يتم علاجها. إذا لاحظت أي من هذه الأعراض:</p><p>اتصل بالطبيب فورا. قد يقرر طبيبك إجراء فحوص على الكبد والكلى أو الدم وقد يخبرك بالتوقف عن تناول سيزيت . في حال اصبت بمتلازمة ستيفنز جونسون أو انحلال البشرة السام فإن طبيبك سوف يطلب منك عدم استخدام لاموتريجين مرة أخرى</p><p>&nbsp;</p><p><strong>آثار جانبية شائعة جدا &quot;قد تؤثر على أكثر من 1 من كل 10 أشخاص&quot;</strong></p><p>صداع الرأس</p><p>الطفح الجلدي</p><p>&nbsp;</p><p><strong>آثار جانبية شائعة &quot;قد يؤثر ذلك على ما يصل إلى 1 من كل 10 أشخاص&quot;</strong></p><p>العدوان أو الهياج</p><p>الشعور بالنعاس أو النعاس</p><p>&nbsp;الشعور بالدوار</p><p>اهتزاز أو ارتعاش</p><p>صعوبة في النوم (الأرق)</p><p>الشعور بالتهيج</p><p>إسهال</p><p>جفاف الفم</p><p>&nbsp;الشعور بالمرض (الغثيان) أو المرض (التقيؤ)</p><p>الشعور بالتعب</p><p>ألم في ظهرك أو مفاصلك، أو في أي مكان آخر</p><p>&nbsp;</p><p><strong>آثار جانبية غير شائعة &quot;قد تؤثر هذه التأثيرات على ما يصل إلى 1 من كل 100 شخص&quot;</strong></p><p>&nbsp;</p><p>التباين وعدم التنسيق (رنح)</p><p>ضعف الرؤية أو عدم وضوح الرؤية</p><p>تساقط الشعر بشكل غير عادي أو ترققه (ثعلبة)</p><p>&nbsp;</p><p><strong>آثار جانبية نادرة &quot;قد تؤثر على ما يصل إلى 1 من كل 1000 شخص&quot;</strong></p><p>&nbsp;رد فعل جلدي مهددة للحياة (متلازمة ستيفنز جونسون)</p><p>مجموعة من الأعراض معا بما في ذلك: الحمى والغثيان والقيء والصداع وتشنج الرقبة والحساسية الشديدة للضوء الساطع. هذا قد يكون ناجما عن التهاب الأغشية التي تغطي الدماغ والحبل الشوكي (التهاب السحايا). هذه الأعراض عادة ما تختفي بمجرد التوقف عن العلاج ولكن إذا استمرت الأعراض أو ازادت سوءا اتصل بطبيبك</p><p>حركات عين سريعة، التي لا يمكن السيطرة عليها (رأرأة)</p><p>حكة في العيون، مع خراجات وجفون قشرية (التهاب الملتحمة)</p><p>&nbsp;</p><p><strong>آثار جانبية نادرة جدا</strong>&nbsp;<strong>قد&nbsp;يؤثر ذلك على ما يصل إلى 1 من كل 10000 شخص</strong></p><p>رد فعل جلدي مهددة للحياة (انحلال البشرة السام)</p><p>&nbsp;ردود الفعل المرتبطة باستخدام الدواء مع فرط الحمضات والأعراض الجهازية</p><p>&nbsp;ارتفاع درجة الحرارة (حمى)</p><p>&nbsp;تورم حول الوجه (وذمة) أو تورم الغدد في الرقبة، الإبط أو الفخذ (اعتلال عقد ليمفاوي)</p><p>&nbsp;تغيرات في وظائف الكبد، والتي سوف تظهر في فحوص الدم أو فشل الكبد</p><p>&nbsp;اضطراب خطير في تخثر الدم، والذي يمكن أن يسبب نزيف غير متوقع أو كدمات (تخثر داخل الأوعية الدموية)</p><p>&nbsp;تغييرات قد تظهر في فحوص الدم - بما في ذلك انخفاض عدد خلايا الدم الحمراء (فقر الدم)، وانخفاض عدد خلايا الدم البيضاء (نقص الكريات البيض، العدلات، ندرة المحببات)، وانخفاض عدد الصفائح الدموية (نقص الصفيحات)، وانخفاض عدد كل هذه الأنواع من الخلايا (قلة الكريات الشاملة) واضطراب في نخاع العظام يسمى فقر الدم اللاتنسجي</p><p>الهلوسة (&#39;رؤية&#39; أو &#39;سماع&#39; أشياء غير حقيقية)</p><p>ارتباك</p><p>&nbsp;شعور &quot;متذبذب&quot; أو غير مستقر عند التحرك</p><p>&bull; حركات الجسم والتي لا يمكن السيطرة عليها، تشنج العضلات والتي لا يمكن السيطرة عليها والتي تؤثر على العينين والرأس والجذع (كنع رقصي) أو غيرها من حركات الجسم غير العادية مثل ارتعاش، هزة أو صلابة</p><p>في المرضى الذين يعانون بالفعل من الصرع، حدثت التشنجات بشكل أكبر</p><p>في المرضى الذين يعانون بالفعل من مرض باركنسون، تفاقمت الأعراض لديهم</p><p>&nbsp;رد فعل شبيه بالذئبة (قد تشمل الأعراض: آلام الظهر أو المفاصل والتي قد تكون مصحوبة أحيانا بالحمى و / أو المرض العام)</p><p>&nbsp;</p><p><strong>الآثار الجانبية الأخرى</strong></p><p>قد وقعت آثار جانبية أخرى في عدد قليل من الناس ولكن ترددها بالضبط غير معروف</p><p>&nbsp;كانت هناك تقارير عن اضطرابات العظام بما في ذلك هشاشة العظام وترقق العظام والكسور. تحقق مع طبيبك أو الصيدلي إذا كنت تأخذ الأدوية المضادة للصرع على المدى الطويل، لديك تاريخ مسبق للاصابة بهشاشة العظام أو تناولت مسبقا المنشطات</p><p>الكوابيس</p><p>&nbsp;</p><p>إذا أصبحت أي من الاثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو مقدم الرعاية الصحية أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ الدواء بعيدا عن متناول و نظر الأطفال</p><p>لا تحفظ الدواء في درجة حرارة أعلى من 30 م</p><p>لا تستعمل سيزيت بعد انقضاء تاريخ الصلاحية المدون على علبة الكرتون بعد كلمة Exp. يشير تاريخ الصلاحية الى اليوم الأخير من الشهر المذكور</p><p>يجب عدم أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد لازمة. ومن شأن هذه التدابير أن تساعد على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: لاموتريجين</p><p>سيزيت&nbsp; 25 ملغم أقراص قابلة للتفتت / قابلة للمضغ: كل قرص يحتوي من 25ملغم لاموتريجين</p><p>سيزيت&nbsp; 50 ملغم أقراص قابلة للتفتت / قابلة للمضغ: كل قرص يحتوي من 50ملغم لاموتريجين</p><p>سيزيت&nbsp; 100 ملغم أقراص قابلة للتفتت / قابلة للمضغ: كل قرص يحتوي من 100ملغم لاموتريجين</p><p>المكونات الأخرى هي: كربونات الكالسيوم، بوفيدون، غليكولات نشا الصوديوم، ألومنيوم مغنيسيوم سيليكات، سكارين الصوديوم، سليلوز هيدروكسيبروبايل منخفض الاستبدال، نكهة الكشمش الاسود ومغنيسيوم ستيرات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص قابلة للتفتت / قابلة للمضغ
الوصف المادي:
سيزيت 25 ملغم أقراص قابلة للتفتت / قابلة للمضغ: أقراص بيضاء مربعة بحواف دائرية قابلة للتفتت مسطحة منقوشة بـ D10 على أحد الجوانب ومتعددة الاوجه من الجهة الاخرى.
سيزيت  50 ملغم أقراص قابلة للتفتت / قابلة للمضغ: أقراص بيضاء دائرية منقوشة بـ T22 على أحد الجوانب وفارغة من الجهة الاخرى.
سيزيت  100 ملغم أقراص قابلة للتفتت / قابلة للمضغ: أقراص بيضاء مربعة بحواف بيضاوية غير مغلفة مسطحة منقوشة بـ E45 على أحد الجوانب ومتعددة الاوجه من الجهة الاخرى.
سيزيت  أقراص قابلة للتفتت / قابلة للمضغ: معبأة في أشرطة من الألومنيوم و PVC/PVDC ، ثم معبأة العلبه في علب كرتونية مع نشرة مطوية.
حجم العبوة: 30 قرص قابل للتفتت / قابل للمضغ (10 أقراص قابلة للتفتت / قابلة للمضغ / شريط، 3 أشرطة / البكيت).
عبوات المستشفيات متوفرة ايضا.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم&nbsp;إس فارما السعودية الرياض ، المملكة العربية السعودية</p><p>info-ksa@mspharma.com</p><p>صنعت بواسطة</p><p>المتحدة للصناعات الدوائية - الأردن لصالح إم إس فارما &ndash; المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             فبراير/2020؛رقم النسخة : SPM190319


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SEIZET® 25mg Dispersible Chewable Tablets	
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amount (mg)/one tablet 	Function 	Material Name 
25	Active Material	Lamotrigine
23.125	Diluent	Calcium Carbonate
0.75	Binder	Povidone
3.125	Disintegrant	Sodium Starch Glycolate
3	Disintegrant	Aluminum Magnesium Silicate
0.625	Sweetening agent	Sodium saccharine
6	Disintegrant	Low-substituted hydroxypropyl cellulose
0.25	Flavoring agent	Black current flavor
0.625	Lubricant	Magnesium Stearate
62.5	Total

For a full list of excipients, see section 6.1 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersible Chewable Tablets

SEIZET® 25mg Dispersible/Chewable Tablets: White rounded square dispersible tablet flat embossed with D10 on one side, multifaceted plain on the other.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Epilepsy</u></strong></p><p><em><u>Adults and adolescents aged 13 years and above</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures associated with Lennox-Gastaut syndrome. <strong>SEIZET<sup>&reg;</sup></strong> is given as adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.</p><p><em><u>Children and adolescents aged 2 to 12 years</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monotherapy of typical absence seizures.</p><p><strong><u>Bipolar disorder</u></strong></p><p><em><u>Adults aged 18 years and above</u></em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes.</p><p><strong>SEIZET<sup>&reg;</sup></strong> is not indicated for the acute treatment of manic or depressive episodes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: Oral.</strong></p><p><strong>SEIZET<sup>&reg;</sup></strong> dispersible/chewable tablets may be chewed, dispersed in a small volume of water (at least enough to cover the whole tablet) or swallowed whole with a little water.</p><p>If the calculated dose of lamotrigine (for example for treatment of children with epilepsy or patients with hepatic impairment) does not equate to whole tablets, the dose to be administered is that equal to the lower number of whole tablets.</p><p><strong><u>Restarting therapy</u></strong></p><p>Prescribers should assess the need for escalation to maintenance dose when restarting <strong>SEIZET<sup>&reg;</sup></strong> in patients who have discontinued <strong>SEIZET<sup>&reg;</sup></strong> for any reason, since the risk of serious rash is associated with high initial doses and exceeding the recommended dose escalation for lamotrigine. The greater the interval of time since the previous dose, the more consideration should be given to escalation to the maintenance dose. When the interval since discontinuing lamotrigine exceeds five half-lives, <strong>SEIZET<sup>&reg;</sup></strong> should generally be escalated to the maintenance dose according to the appropriate schedule.</p><p>It is recommended that <strong>SEIZET<sup>&reg;</sup></strong> not be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk.</p><p><strong><u>Epilepsy</u></strong></p><p>The recommended dose escalation and maintenance doses for adults and adolescents aged 13 years and above (Table 1) and for children and adolescents aged 2 to 12 years (Table 2) are given below. Because of a risk of rash the initial dose and subsequent dose escalation should not be exceeded.</p><p>When concomitant AEDs are withdrawn or other AEDs/medicinal products are added on to treatment regimes containing lamotrigine, consideration should be given to the effect this may have on lamotrigine pharmacokinetics.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Table 1: Adults and adolescents aged 13 years and above &ndash; recommended treatment regimen in epilepsy</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:106%"><tbody><tr><td style="vertical-align:top"><p>Treatment regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Usual maintenance dose</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Monotherapy:</strong></p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved</p><p>500 mg/day has been required by some patients to achieve desired response</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong> (inhibitor of lamotrigine glucuronidation)<strong>:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>12.5 mg/day</p><p>(given as 25 mg on alternate days)</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 25 - 50 mg every one to two weeks until optimal response is achieved</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 - 400 mg/day</p><p>(two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 100 mg every one to two weeks until optimal response is achieved</p><p>700 mg/day has been required by some patients to achieve desired response</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation):</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 - 200 mg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 50 - 100 mg every one to two weeks until optimal response is achieved</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Table 2: Children and adolescents aged 2 to 12 years - recommended treatment regimen in epilepsy (total daily dose in mg/kg body weight/day)</u></em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:106%"><tbody><tr><td style="vertical-align:top"><p>Treatment regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Usual maintenance dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>Monotherapy of typical absence seizures:</strong></p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>1 &ndash; 15 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg/day every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200mg/day</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong> (inhibitor of lamotrigine glucuronidation )<strong>:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any other concomitant medicinal products</p></td><td style="vertical-align:top"><p>0.15 mg/kg/day*</p><p>(once a day)</p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>1 - 5 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.3 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200 mg/day</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>1.2 mg/kg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>5 - 15 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 1.2 mg/kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 400 mg/day</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation</strong> :</p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation</p></td><td style="vertical-align:top"><p>0.3 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>0.6 mg/kg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>1 - 10 mg/kg/day</p><p>(once a day or two divided doses)</p><p>To achieve maintenance, doses may be increased by maximum of 0.6 mg/kg every one to two weeks until optimal response is achieved, with a maximum of maintenance dose of 200 mg/day</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* If the calculated daily dose in patients taking valproate is 1 mg or more but less than 2 mg, then <strong>SEIZET<sup>&reg;</sup></strong> 25 mg dispersible/chewable tablets may be taken on alternate days for the first two weeks. If the calculated daily dose in patients taking valproate is less than 1 mg, then <strong>SEIZET<sup>&reg;</sup></strong> should not be administered.</p></td></tr></tbody></table><p>To ensure a therapeutic dose is maintained the weight of a child must be monitored and the dose reviewed as weight changes occur. It is likely that patients aged two to six years will require a maintenance dose at the higher end of the recommended range.</p><p>If epileptic control is achieved with adjunctive treatment, concomitant AEDs may be withdrawn and patients continued on <strong>SEIZET<sup>&reg;</sup></strong> monotherapy.</p><p><em><u>Children below 2 years</u></em></p><p>There are limited data on the efficacy and safety of lamotrigine for adjunctive therapy of partial seizures in children aged 1 month to 2 years. There are no data in children below 1 month of age. Thus <strong>SEIZET<sup>&reg;</sup></strong> is not recommended for use in children below 2 years of age. If, based on clinical need, a decision to treat is nevertheless taken.</p><p><strong><u>Bipolar disorder</u></strong></p><p>The recommended dose escalation and maintenance doses for adults of 18 years of age and above are given in the tables below. The transition regimen involves escalating the dose of lamotrigine to a maintenance stabilisation dose over six weeks (Table 3) after which other psychotropic medicinal products and/or AEDs can be withdrawn, if clinically indicated (Table 4). The dose adjustments following addition of other psychotropic medicinal products and/or AEDs are also provided below (Table 5). Because of the risk of rash the initial dose and subsequent dose escalation should not be exceeded.</p><p><em><u>Table 3: Adults aged 18 years and above - recommended dose escalation to the maintenance total daily stabilisation dose in treatment of bipolar disorder</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Weeks 1 + 2</p></td><td style="vertical-align:top"><p>Weeks 3 + 4</p></td><td style="vertical-align:top"><p>Week 5</p></td><td style="vertical-align:top"><p>Target Stabilisation Dose (Week 6)*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Monotherapy with lamotrigine OR adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>200 mg/day - usual target dose for optimal response</p><p>(once a day or two divided doses)</p><p>Doses in the range 100 - 400 mg/day</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Adjunctive therapy WITH valproate</strong> (inhibitor of lamotrigine glucuronidation )<strong>: </strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used with valproate regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>12.5 mg/day</p><p>(given as 25 mg on alternate days)</p></td><td style="vertical-align:top"><p>25 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day or two divided doses)</p></td><td style="vertical-align:top"><p>100 mg/day - usual target dose for optimal response</p><p>(once a day or two divided doses)</p><p>Maximum dose of 200 mg/day can be used depending on clinical response</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used without valproate but with:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>50 mg/day</p><p>(once a day)</p></td><td style="vertical-align:top"><p>100 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>200 mg/day</p><p>(two divided doses)</p></td><td style="vertical-align:top"><p>300 mg/day in week 6, if necessary increasing to usual target dose of 400 mg/day in week 7, to achieve optimal response</p><p>(two divided doses)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known, the dose escalation as recommended for lamotrigine with concurrent valproate, should be used.</p></td></tr></tbody></table><p>* The Target stabilisation dose will alter depending on clinical response</p><p><em><u>Table 4: Adults aged 18 years and above - maintenance stabilisation total daily dose following withdrawal of concomitant medicinal products in treatment of bipolar disorder</u></em></p><p>Once the target daily maintenance stabilisation dose has been achieved, other medicinal products may be withdrawn as shown below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Current lamotrigine stabilisation dose (prior to withdrawal)</p></td><td style="vertical-align:top"><p>Week 1 (beginning with withdrawal)</p></td><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>Week 3 onwards *</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Withdrawal of valproate</strong> (inhibitor of lamotrigine glucuronidation ), depending on original dose of lamotrigine<strong>:</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>When valproate is withdrawn, double the stabilisation dose, not exceeding an increase of more than 100 mg/week</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (200 mg/day)</p><p>(two divided doses)</p></td></tr><tr><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>Maintain this dose (400 mg/day)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Withdrawal of inducers of lamotrigine glucuronidation</strong>, depending on original dose of lamotrigine<strong>:</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>This dosage regimen should be used when the following are withdrawn:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>225 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Withdrawal of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are withdrawn</p></td><td colspan="4" style="vertical-align:top"><p>Maintain target dose achieved in dose escalation (200 mg/day; two divided doses)</p><p>(dose range 100 - 400 mg/day)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen recommended for lamotrigine is to initially maintain the current dose and adjust the lamotrigine treatment based on clinical response.</p></td></tr></tbody></table><p>* Dose may be increased to 400 mg/day as needed</p><p><em><u>Table 5: Adults aged 18 years and above - adjustment of lamotrigine daily dosing following the addition of other medicinal products in treatment of bipolar disorder </u></em></p><p>There is no clinical experience in adjusting the lamotrigine daily dose following the addition of other medicinal products. However, based on interaction with other medicinal products, the following recommendations can be made:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Treatment Regimen</p></td><td style="vertical-align:top"><p>Current lamotrigine stabilisation dose (prior to addition)</p></td><td style="vertical-align:top"><p>Week 1 (beginning with addition)</p></td><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>Week 3 onwards</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Addition of valproate</strong> (inhibitor of lamotrigine glucuronidation ), depending on original dose of lamotrigine<strong>:</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>This dosage regimen should be used when valproate is added regardless of any concomitant medicinal products</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (100 mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (150 mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>400 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td colspan="2" style="vertical-align:top"><p>Maintain this dose (200 mg/day)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Addition of inducers of lamotrigine glucuronidation in patients NOT taking valproate</strong>, depending on original dose of lamotrigine<strong>: </strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>This dosage regimen should be used when the following are added without valproate:</p><p>phenytoin</p><p>carbamazepine</p><p>phenobarbitone</p><p>primidone</p><p>rifampicin</p><p>lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td><td style="vertical-align:top"><p>400 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>225 mg/day</p></td><td style="vertical-align:top"><p>300 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>100 mg/day</p></td><td style="vertical-align:top"><p>150 mg/day</p></td><td style="vertical-align:top"><p>200 mg/day</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Addition of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation:</strong></p></td></tr><tr><td style="vertical-align:top"><p>This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are added</p></td><td colspan="4" style="vertical-align:top"><p>Maintain target dose achieved in dose escalation (200 mg/day; dose range 100-400 mg/day)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known, the treatment regimen as recommended for lamotrigine with concurrent valproate, should be used.</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Discontinuation of <strong>SEIZET<sup>&reg;</sup></strong> in patients with bipolar disorder</u></em></p><p>There was no increase in the incidence, severity or type of adverse reactions following abrupt termination of lamotrigine versus placebo. Therefore, patients may terminate <strong>SEIZET<sup>&reg;</sup></strong> without a step-wise reduction of dose.</p><p><em><u>Children and adolescents below 18 years</u></em></p><p><strong>SEIZET<sup>&reg;</sup></strong> is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy and showed increased reporting of suicidality.</p><p><u>General dosing recommendations for <strong>SEIZET<sup>&reg;</sup></strong> in special patient populations</u></p><p><em><u>Women taking hormonal contraceptives</u></em></p><p>The use of an ethinyloestradiol/levonorgestrel (30 &mu;g/150 &mu;g) combination increases the clearance of lamotrigine by approximately two-fold, resulting in decreased lamotrigine levels. Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) may be needed to attain a maximal therapeutic response. During the pill-free week, a two-fold increase in lamotrigine levels has been observed. Dose-related adverse events cannot be excluded. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods).</p><p><em>Starting hormonal contraceptives in patients already taking maintenance doses of lamotrigine and NOT taking inducers of lamotrigine glucuronidation</em></p><p>The maintenance dose of lamotrigine will in most cases need to be increased by as much as two-fold. It is recommended that from the time that the hormonal contraceptive is started, the lamotrigine dose is increased by 50 to 100 mg/day every week, according to the individual clinical response. Dose increases should not exceed this rate, unless the clinical response supports larger increases. Measurement of serum lamotrigine concentrations before and after starting hormonal contraceptives may be considered, as confirmation that the baseline concentration of lamotrigine is being maintained. If necessary, the dose should be adapted. In women taking a hormonal contraceptive that includes one week of inactive treatment (&quot;pill-free week&quot;), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods.</p><p><em>Stopping hormonal contraceptives in patients already taking maintenance doses of lamotrigine and NOT taking inducers of lamotrigine glucuronidation</em></p><p>The maintenance dose of lamotrigine will in most cases need to be decreased by as much as 50%. It is recommended to gradually decrease the daily dose of lamotrigine by 50-100 mg each week (at a rate not exceeding 25% of the total daily dose per week) over a period of 3 weeks, unless the clinical response indicates otherwise. Measurement of serum lamotrigine concentrations before and after stopping hormonal contraceptives may be considered, as confirmation that the baseline concentration of lamotrigine is being maintained. In women who wish to stop taking a hormonal contraceptive that includes one week of inactive treatment (&quot;pill-free week&quot;), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. Samples for assessment of lamotrigine levels after permanently stopping the contraceptive pill should not be collected during the first week after stopping the pill.</p><p><em>Starting lamotrigine in patients already taking hormonal contraceptives</em></p><p>Dose escalation should follow the normal dose recommendation described in the tables.</p><p><em>Starting and stopping hormonal contraceptives in patients already taking maintenance doses of lamotrigine and TAKING inducers of lamotrigine glucuronidation</em></p><p>Adjustment to the recommended maintenance dose of lamotrigine may not be required.</p><p><em><u>Use with atazanavir/ritonavir</u></em></p><p>No adjustments to the recommended dose escalation of lamotrigine should be necessary when lamotrigine is added to the existing atazanavir/ritonavir therapy.</p><p>In patients already taking maintenance doses of lamotrigine and not taking glucuronidation inducers, the lamotrigine dose may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued. Plasma lamotrigine monitoring should be conducted before and during 2 weeks after starting or stopping atazanavir/ritonavir, in order to see if lamotrigine dose adjustment is needed.</p><p><em><u>Use with lopinavir/ritonavir</u></em></p><p>No adjustments to the recommended dose escalation of lamotrigine should be necessary when lamotrigine is added to the existing lopinavir/ritonavir therapy.</p><p>In patients already taking maintenance doses of lamotrigine and not taking glucuronidation inducers, the lamotrigine dose may need to be increased if lopinavir/ritonavir is added, or decreased if lopinavir/ritonavir is discontinued. Plasma lamotrigine monitoring should be conducted before and during 2 weeks after starting or stopping lopinavir/ritonavir, in order to see if lamotrigine dose adjustment is needed.</p><p><em><u>Elderly (above 65 years)</u></em></p><p>No dosage adjustment from the recommended schedule is required. The pharmacokinetics of lamotrigine in this age group do not differ significantly from a non-elderly adult population.</p><p><em><u>Renal impairment</u></em></p><p>Caution should be exercised when administering <strong>SEIZET<sup>&reg;</sup></strong> to patients with renal failure. For patients with end-stage renal failure, initial doses of lamotrigine should be based on patients&#39; concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment.</p><p><em><u>Hepatic impairment</u></em></p><p>Initial, escalation and maintenance doses should generally be reduced by approximately 50% in patients with moderate (Child-Pugh grade B) and 75% in severe (Child-Pugh grade C) hepatic impairment. Escalation and maintenance doses should be adjusted according to clinical response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Skin rash</u></p><p>There have been reports of adverse skin reactions, which have generally occurred within the first eight weeks after initiation of lamotrigine treatment.</p><p>The majority of rashes are mild and self-limiting, however serious rashes requiring hospitalisation and discontinuation of lamotrigine have also been reported. These have included potentially life-threatening rashes such as Stevens&ndash;Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); also known as hypersensitivity syndrome (HSS).</p><p>The incidence of serious skin rashes is approximately 1 in 500 in epilepsy patients. Approximately half of these cases have been reported as Stevens&ndash;Johnson syndrome (1 in 1000). In patients with bipolar disorder, the incidence of serious rash is approximately 1 in 1000.</p><p>The risk of serious skin rashes in children is higher than in adults. Available data suggest the incidence of rashes associated with hospitalisation in children is from 1 in 300 to 1 in 100.</p><p>In children, the initial presentation of a rash can be mistaken for an infection, physicians should consider the possibility of a reaction to lamotrigine treatment in children that develop symptoms of rash and fever during the first eight weeks of therapy.</p><p>Additionally the overall risk of rash appears to be strongly associated with:</p><p>- high initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy</p><p>- concomitant use of valproate.</p><p>Caution is also required when treating patients with a history of allergy or rash to other AEDs as the frequency of non-serious rash after treatment with lamotrigine was approximately three times higher in these patients than in those without such history.</p><p>All patients (adults and children) who develop a rash should be promptly evaluated and <strong>SEIZET<sup>&reg;</sup></strong> withdrawn immediately unless the rash is clearly not related to lamotrigine treatment. It is recommended that <strong>SEIZET<sup>&reg;</sup></strong> not be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk. If the patient has developed SJS or TEN with the use of lamotrigine, treatment with lamotrigine must not be restarted in this patient at any time.</p><p>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema, abnormalities of the blood and liver and aseptic meningitis. The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation and multiorgan failure. It is important to note that early manifestations of hypersensitivity (for example fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present the patient should be evaluated immediately and <strong>SEIZET&reg;</strong> discontinued if an alternative aetiology cannot be established.</p><p>Aseptic meningitis was reversible on withdrawal of the drug in most cases, but recurred in a number of cases on re-exposure to lamotrigine. Re-exposure resulted in a rapid return of symptoms that were frequently more severe. Lamotrigine should not be restarted in patients who have discontinued due to aseptic meningitis associated with prior treatment of lamotrigine.</p><p><u>Clinical worsening and suicide risk</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with AEDs in several indications. a small increased risk of suicidal ideation and behavior have been shown.</p><p>The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lamotrigine.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>In patients with bipolar disorder, worsening of depressive symptoms and/or the emergence of suicidality may occur whether or not they are taking medications for bipolar disorder, including <strong>SEIZET<sup>&reg;</sup></strong>. Therefore patients receiving <strong>SEIZET<sup>&reg;</sup></strong> for bipolar disorder should be closely monitored for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes. Certain patients, such as those with a history of suicidal behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, may be at a greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient&#39;s presenting symptoms.</p><p><u>Hormonal contraceptives</u></p><p><em><u>Effects of hormonal contraceptives on lamotrigine efficacy</u></em></p><p>The use of an ethinyloestradiol/levonorgestrel (30 &mu;g/150 &mu;g) combination increases the clearance of lamotrigine by approximately two-fold resulting in decreased lamotrigine levels. A decrease in lamotrigine levels has been associated with loss of seizure control. Following titration, higher maintenance doses of lamotrigine (by as much as two-fold) will be needed in most cases to attain a maximal therapeutic response. When stopping hormonal contraceptives, the clearance of lamotrigine may be halved. Increases in lamotrigine concentrations may be associated with dose-related adverse events. Patients should be monitored with respect to this.</p><p>In women not already taking an inducer of lamotrigine glucuronidation and taking a hormonal contraceptive that includes one week of inactive treatment (for example &quot;pill-free week&quot;), gradual transient increases in lamotrigine levels will occur during the week of inactive treatment. Variations in lamotrigine levels of this order may be associated with adverse effects. Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods).</p><p>The interaction between other oral contraceptive or HRT treatments and lamotrigine have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters.</p><p><em><u>Effects of lamotrigine on hormonal contraceptive efficacy</u></em></p><p>When lamotrigine and a hormonal contraceptive (ethinyloestradiol/levonorgestrel combination) are administered in combination, there is a modest increase in levonorgestrel clearance and changes in serum FSH and LH. The impact of these changes on ovarian ovulatory activity is unknown. However, the possibility of these changes resulting in decreased contraceptive efficacy in some patients taking hormonal preparations with lamotrigine cannot be excluded. Therefore patients should be instructed to promptly report changes in their menstrual pattern, i.e. breakthrough bleeding.</p><p><u>Dihydrofolate reductase</u></p><p>Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase, hence there is a possibility of interference with folate metabolism during long-term therapy. However, during prolonged human dosing, lamotrigine did not induce significant changes in the haemoglobin concentration, mean corpuscular volume, or serum or red blood cell folate concentrations up to 1 year or red blood cell folate concentrations for up to 5 years.</p><p><u>Renal failure</u></p><p>In end stage renal failure patiants, plasma concentrations of lamotrigine were not significantly altered. However, accumulation of the glucuronide metabolite is to be expected; caution should therefore be exercised in treating patients with renal failure.</p><p><u>Patients taking other preparations containing lamotrigine</u></p><p><strong>SEIZET&reg;</strong> should not be administered to patients currently being treated with any other preparation containing lamotrigine without consulting a doctor.</p><p><u>Development in children</u></p><p>There are no data on the effect of lamotrigine on growth, sexual maturation and cognitive, emotional and behavioural developments in children.</p><p><u>Precautions relating to epilepsy</u></p><p>As with other AEDs, abrupt withdrawal of <strong>SEIZET<sup>&reg;</sup></strong> may provoke rebound seizures. Unless safety concerns (for example rash) require an abrupt withdrawal, the dose of <strong>SEIZET<sup>&reg;</sup></strong> should be gradually decreased over a period of two weeks.</p><p>There are reports in the literature that severe convulsive seizures including status epilepticus may lead to rhabdomyolysis, multiorgan dysfunction and disseminated intravascular coagulation, sometimes with fatal outcome. Similar cases have occurred in association with the use of lamotrigine.</p><p>A clinically significant worsening of seizure frequency instead of an improvement may be observed. In patients with more than one seizure type, the observed benefit of control for one seizure type should be weighed against any observed worsening in another seizure type.</p><p>Myoclonic seizures may be worsened by lamotrigine.</p><p>There is a suggestion in the data that responses in combination with enzyme inducers is less than in combination with non-enzyme inducing antiepileptic agents. The reason is unclear.</p><p>In children taking lamotrigine for the treament of typical absence seizures, efficacy may not be maintained in all patients.</p><p><u>Precautions relating to bipolar disorder</u></p><p><em><u>Children and adolescents below 18 years</u></em></p><p>Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adults: UDP-glucuronyl transferases have been identified as the enzymes responsible for metabolism of lamotrigine. There is no evidence that lamotrigine causes clinically significant induction or inhibition of hepatic oxidative drug-metabolising enzymes, and interactions between lamotrigine and medicinal products metabolised by cytochrome P450 enzymes are unlikely to occur.</p><p>Lamotrigine may induce its own metabolism but the effect is modest and unlikely to have significant clinical consequences.</p><p><em><u>Table 6: Effects of other medicinal products on glucuronidation of lamotrigine</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products that significantly inhibit glucuronidation of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Medicinal products that significantly induce glucuronidation of lamotrigine</strong></p></td><td style="vertical-align:top"><p><strong>Medicinal products that do not significantly inhibit or induce glucuronidation of lamotrigine</strong></p></td></tr><tr><td style="vertical-align:top"><p>Valproate</p></td><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Oxcarbazepine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Felbamate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenobarbitone</p></td><td style="vertical-align:top"><p>Gabapentin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Primidone</p></td><td style="vertical-align:top"><p>Levetiracetam</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rifampicin</p></td><td style="vertical-align:top"><p>Pregabalin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lopinavir/ritonavir</p></td><td style="vertical-align:top"><p>Topiramate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ethinyloestradiol/ levonorgestrel combination**</p></td><td style="vertical-align:top"><p>Zonisamide</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atazanavir/ritonavir*</p></td><td style="vertical-align:top"><p>Lithium</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Buproprion</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Olanzapine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aripiprazole</p></td></tr></tbody></table><p>*For dosing guidance.</p><p>**Other oral contraceptive and HRT treatments have not been studied, though they may similarly affect lamotrigine pharmacokinetic parameters&nbsp;</p><p><u>Interactions involving antiepileptic drugs</u></p><p>Valproate, which inhibits the glucuronidation of lamotrigine, reduces the metabolism of lamotrigine and increases the mean half-life of lamotrigine nearly two-fold. In patients receiving concomitant therapy with valproate, the appropriate treatment regimen should be used.</p><p>Certain AEDs (such as phenytoin, carbamazepine, phenobarbitone and primidone) which induce hepatic drug-metabolising enzymes induce the glucuronidation of lamotrigine and enhance the metabolism of lamotrigine. In patients receiving concomitant therapy with phenytoin, carbamazepine, pheonbarbitone or primidone, the appropriate treatment regimen should be used.</p><p>There have been reports of central nervous system events including dizziness, ataxia, diplopia, blurred vision and nausea in patients taking carbamazepine following the introduction of lamotrigine. These events usually resolve when the dose of carbamazepine is reduced. A similar effect was seen during a study of lamotrigine and oxcarbazepine in healthy adult volunteers, but dose reduction was not investigated.</p><p>There are reports in the literature of decreased lamotrigine levels when lamotrigine was given in combination with oxcarbazepine. However, Therefore in patients receiving concomitant therapy with oxcarbazepine, the treatment regimen for lamotrigine adjunctive therapy without valproate and without inducers of lamotrigine glucuronidation should be used.</p><p><s>C</s>oadministration of felbamate (1200 mg twice daily) with lamotrigine (100 mg twice daily for 10 days) appeared to have no clinically relevant effects on the pharmacokinetics of lamotrigine.</p><p>Based on a retrospective analysis of plasma levels in patients who received lamotrigine both with and without gabapentin, gabapentin does not appear to change the apparent clearance of lamotrigine.</p><p>lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.</p><p>Potential interactions between levetiracetam and lamotrigine were assessed by evaluating serum concentrations of both agents. These data indicate that lamotrigine does not influence the pharmacokinetics of levetiracetam and that levetiracetam does not influence the pharmacokinetics of lamotrigine.</p><p>Steady-state trough plasma concentrations of lamotrigine were not affected by concomitant pregabalin (200 mg, 3 times daily) administration. There are no pharmacokinetic interactions between lamotrigine and pregabalin.</p><p>Topiramate resulted in no change in plasma concentrations of lamotrigine. Administration of lamotrigine resulted in a 15% increase in topiramate concentrations.</p><p>In patients with epilepsy, coadministration of zonisamide (200 to 400 mg/day) with lamotrigine (150 to 500 mg/day) for 35 days had no significant effect on the pharmacokinetics of lamotrigine.</p><p>Although changes in the plasma concentrations of other AEDs have been reported, No evidence that lamotrigine affects the plasma concentrations of concomitant AEDs. Does not displace other AEDs from protein binding sites.</p><p><u>Interactions involving other psychoactive agents</u></p><p>The pharmacokinetics of lithium were not altered by co-administration of lamotrigine.</p><p>Multiple oral doses of bupropion had no statistically significant effects on the single dose pharmacokinetics of lamotrigine and had only a slight increase in the AUC of lamotrigine glucuronide.</p><p>Lamotrigine at 200 mg did not affect the pharmacokinetics of olanzapine.</p><p>&nbsp;</p><p>Multiple oral doses of lamotrigine 400 mg daily had no clinically significant effect on the single dose pharmacokinetics of 2 mg risperidone Following the co-administration of risperidone with lamotrigine volunteers reported somnolence compared to 1 out of 20 when risperidone was given alone, and none when lamotrigine was administered alone.</p><p>In adult patients with bipolar I disorder, receiving an established regimen of lamotrigine (100-400 mg/day), doses of aripiprazole were increased. An average reduction of approximately 10% in C<sub>max&nbsp;</sub>and AUC of lamotrigine was observed. An effect of this magnitude is not expected to be of clinical consequence.</p><p>Indicated that the formation of lamotrigine&#39;s primary metabolite, the 2-N-glucuronide, was minimally inhibited by co-incubation with amitriptyline, bupropion, clonazepam, haloperidol or lorazepam.</p><p>&nbsp;</p><p>These experiments also suggested that metabolism of lamotrigine was unlikely to be inhibited by clozapine, fluoxetine, phenelzine, risperidone, sertraline or trazodone. In bufuralol metabolism using human liver microsome preparations suggested that lamotrigine would not reduce the clearance of medicinal products metabolised predominantly by CYP2D6.</p><p><u>Interactions involving hormonal contraceptives</u></p><p><em><u>Effect of hormonal contraceptives on lamotrigine pharmacokinetics</u></em></p><p><s>E</s>thinyloestradiol/ levonorgestrel in a combined oral contraceptive pill caused an approximately two-fold increase in lamotrigine oral clearance, resulting in an average reduction in lamotrigine AUC and Cmax, respectively. Serum lamotrigine concentrations increased during the course of the week of inactive treatment (including the &quot;pill-free&quot; week), with pre-dose concentrations at the end of the week of inactive treatment being, on average, approximately two-fold higher than during co-therapy. No adjustments to the recommended dose escalation guidelines for lamotrigine should be necessary solely based on the use of hormonal contraceptives, but the maintenance dose of lamotrigine will need to be increased or decreased in most cases when starting or stopping hormonal contraceptives.</p><p><em><u>Effect of lamotrigine on hormonal contraceptive pharmacokinetics</u></em></p><p><s>A</s> steady state dose of 300 mg lamotrigine had no effect on the pharmacokinetics of the ethinyloestradiol component of a combined oral contraceptive pill. A modest increase in oral clearance of the levonorgestrel component was observed, resulting in an average reduction in levonorgestrel AUC and Cmax, respectively. Measurement of serum FSH, LH and oestradiol during the study indicated some loss of suppression of ovarian hormonal activity in some women, although measurement of serum progesterone indicated that there was no hormonal evidence of ovulation. The impact of the modest increase in levonorgestrel clearance, and the changes in serum FSH and LH, on ovarian ovulatory activity is unknown. The effects of doses of lamotrigine other than 300 mg/day have not been studied and studies with other female hormonal preparations have not been conducted.</p><p><u>Interactions involving other medicinal products</u></p><p>Rifampicin increased lamotrigine clearance and decreased lamotrigine half-life due to induction of the hepatic enzymes responsible for glucuronidation. In patients receiving concomitant therapy with rifampicin, the appropriate treatment regimen should be used.</p><p>Lopinavir/ritonavir approximately halved the plasma concentrations of lamotrigine, probably by induction of glucuronidation. In patients receiving concomitant therapy with lopinavir/ritonavir, the appropriate treatment regimen should be used.</p><p>Atazanavir/ritonavir (300 mg/100 mg) administered for 9 days reduced the plasma AUC and Cmax of lamotrigine (single 100 mg dose) by an average of 32% and 6%, respectively. In patients receiving concomitant therapy with atazanavir/ritonavir, the appropriate treatment regimen should be used.</p><p>Data demonstrate that lamotrigine, but not the N(2)-glucuronide metabolite, is an inhibitor of OCT 2 at potentially clinically relevant concentrations. These data demonstrate that lamotrigine is a more potent&nbsp; inhibitor of OCT 2 than cimetidine, with IC<sub>50</sub>&nbsp;values of 53.8 &micro;M and 186 &micro;M, respectively. Co-administration of lamotrigine with renally excreted medicinal products which are substrates of OCT2 (e.g. metformin, gabapentin and varenicline) may result in increased plasma levels of these drugs.</p><p>&nbsp;</p><p>The clinical significance of this has not been clearly defined, however care should be taken in patients co-administered with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Risk related to antiepileptic drugs in general</u></p><p>Specialist advice should be given to women who are of childbearing potential. The need for treatment with AEDs should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of AED therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child.</p><p>The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with AEDs compared with the expected incidence in the general population of approximately 3%. The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects. Therapy with multiple AEDs is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible.</p><p><u>Risk related to lamotrigine</u></p><p><em><u>Pregnancy</u></em></p><p>Data are still too limited to exclude a moderate increase in the risk of oral clefts.</p><p>&nbsp;If therapy with <strong>SEIZET<sup>&reg;</sup></strong> is considered necessary during pregnancy, the lowest possible therapeutic dose is recommended.</p><p>Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase and could therefore theoretically lead to an increased risk of embryofoetal damage by reducing folic acid levels. Intake of folic acid when planning pregnancy and during early pregnancy may be considered.</p><p>Physiological changes during pregnancy may affect lamotrigine levels and/or therapeutic effect. There have been reports of decreased lamotrigine plasma levels during pregnancy with a potential risk of loss of seizure control. After birth lamotrigine levels may increase rapidly with a risk of dose-related adverse events. Therefore lamotrigine serum concentrations should be monitored before, during and after pregnancy, as well as shortly after birth. If necessary, the dose should be adapted to maintain the lamotrigine serum concentration at the same level as before pregnancy, or adapted according to clinical response. In addition, dose-related undesirable effects should be monitored after birth.</p><p><em><u>Lactation</u></em></p><p>Lamotrigine has been reported to pass into breast milk in highly variable concentrations, resulting in total lamotrigine levels in infants of up to approximately 50% of the mother&#39;s. Therefore, in some breast-fed infants, serum concentrations of lamotrigine may reach levels at which pharmacological effects occur. Among a limited group of exposed infants, no adverse effects were observed.</p><p>&nbsp;</p><p>The potential benefits of breast-feeding should be weighed against the potential risk of adverse effects occurring in the infant. Should a woman decide to breast-feed while on therapy with lamotrigine, the infant should be monitored for adverse effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As there is individual variation in response to all AED therapy, patients taking <strong>SEIZET<sup>&reg;</sup></strong> to treat epilepsy should consult their physician on the specific issues of driving and epilepsy.</p><p>No studies on the effects on the ability to drive and use machines have been performed. lamotrigine adverse reactions of a neurological character such as dizziness and diplopia have been reported. Therefore, patients should see how <strong>SEIZET&reg;</strong> therapy affects them before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following convention has been utilised for the classification of undesirable effects:- Very common (<u>&gt;</u>1/10); common (<u>&gt;</u>1/100 to &lt;1/10); uncommon (<u>&gt;</u>1/1000 to &lt;1/100); rare (<u>&gt;</u>1/10,000 to &lt;1/1000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Haematological abnormalities<sup>1</sup> including neutropenia, leucopenia, anaemia, thrombocytopenia, pancytopenia, aplastic anaemia, agranulocytosis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Lymphadenopathy<sup>1</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity syndrome<sup>2 </sup>(including such symptoms as, fever, lymphadenopathy, facial oedema, abnormalities of the blood and liver, disseminated intravascular coagulation, multi organ failure).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Aggression, irritability</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Confusion, hallucinations, tics</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Nightmares</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence, dizziness, tremor, insomnia agitation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Ataxia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nystagmus</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Unsteadiness, movement disorders, worsening of Parkinson&#39;s disease, extrapyramidal effects, choreoathetosis, increase in seizure frequency</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Aseptic meningitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Diplopia, blurred vision</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea, dry mouth</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatic dysfunction<sup>4</sup>, increased liver function tests</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Skin rash<sup>5</sup></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Stevens&ndash;Johnson Syndrome</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Lupus-like reactions</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Tiredness, pain, back pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><sup>1 </sup>Haematological abnormalities and lymphadenopathy may or may not be associated with the hypersensitivity syndrome.</p><p><sup>2 </sup>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema and abnormalities of the blood and liver. The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation and multiorgan failure. It is important to note that early manifestations of hypersensitivity (for example fever, lymphadenopathy) may be present even though rash is not evident. If such signs and symptoms are present, the patient should be evaluated immediately and <strong>SEIZET<sup>&reg;</sup></strong> discontinued if an alternative aetiology cannot be established.</p><p>There have been reports that lamotrigine may worsen parkinsonian symptoms in patients with pre-existing Parkinson&#39;s disease, and isolated reports of extrapyramidal effects and choreoathetosis in patients without this underlying condition.</p><p><sup>4 </sup>Hepatic dysfunction usually occurs in association with hypersensitivity reactions but isolated cases have been reported without overt signs of hypersensitivity.</p><p><sup>5 </sup>skin rashes occurred in up to 8-12% of patients taking lamotrigine and in 5-6% of patients taking placebo. The skin rashes led to the withdrawal of lamotrigine treatment in 2% of patients.</p><p>&nbsp;</p><p>The rash, usually macropapular in appearance, generally appears within eight weeks of starting treatment and resolves on withdrawal of <strong>SEIZET<sup>&reg;</sup></strong>. Serious potentially life-threatening skin rashes, including Stevens&ndash;Johnson syndrome and toxic epidermal necrolysis (Lyell&#39;s Syndrome) have been reported. Although the majority recover on withdrawal of lamotrigine treatment, some patients experience irreversible scarring and there have been rare cases of associated death.</p><p>The overall risk of rash appears to be strongly associated with:</p><p>- High initial doses of lamotrigine and exceeding the recommended dose escalation of lamotrigine therapy</p><p>- Concomitant use of valproate.</p><p>Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms.</p><p>There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with lamotrigine. The mechanism by which lamotrigine affects bone metabolism has not been identified.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p>Acute ingestion of doses in excess of 10 to 20 times the maximum therapeutic dose has been reported, including fatal cases. Overdose has resulted in symptoms including nystagmus, ataxia, impaired consciousness, grand mal convulsion and coma. QRS broadening (intraventricular conduction delay) has also been observed in overdose patients. Broadening of QRS duration to more than 100 msec may be associated with more severe toxicity.</p><p><u>Treatment</u></p><p>In the event of overdose, the patient should be admitted to hospital and given appropriate supportive therapy. Therapy aimed at decreasing absorption (activated charcoal) should be performed if indicated. Further management should be as clinically indicated. There is no experience with haemodialysis as treatment of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> other antiepileptics, <strong>ATC code:</strong> N03AX09.</p><p><strong><u>Mechanism of action</u></strong></p><p>lamotrigine is a use- and voltage-dependent blocker of voltage gated sodium channels. It inhibits sustained repetitive firing of neurones and inhibits release of glutamate (the neurotransmitter which plays a key role in the generation of epileptic seizures). These effects are likely to contribute to the anticonvulsant properties of lamotrigine.</p><p>In contrast, the mechanisms by which lamotrigine exerts its therapeutic action in bipolar disorder have not been established, although interaction with voltage gated sodium channels is likely to be important.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Carbamazepine significantly impaired fine visual motor co-ordination and eye movements, while increasing both body sway and heart rate.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety in children aged 1 to 24 months</u></p><p>The efficacy and safety of adjunctive therapy in partial seizures in patients aged 1 to 24 months has been evaluated.</p><p>The difference was not statistically significant. The safety profile of lamotrigine in children aged 1 month to 2 years was similar to that in older children except that clinically significant worsening of seizures (&gt;=50%) was reported more often in children under 2 years of age (26%) as compared to older children (14%).</p><p><u>Clinical efficacy and safety in Lennox-Gastaut syndrome</u></p><p>There are no data for monotherapy in seizures associated with Lennox-Gastaut syndrome.</p><p><u>Clinical efficacy in the prevention of mood episodes in patients with bipolar disorder</u></p><p>The efficacy of lamotrigine in the prevention of mood episodes in patients with bipolar I disorder has been evaluated.</p><p>In supportive analyses of time to first depressive episode and time to first manic/hypomanic or mixed episode, the lamotrigine-treated patients had significantly longer times to first depressive episode than placebo patients, and the treatment difference with respect to time to manic/hypomanic or mixed episodes was not statistically significant.</p><p>&nbsp;</p><p>The efficacy of lamotrigine in combination with mood stabilisers has not been adequately studied.</p><p><u>Children (10-12 years of age) and Adolescents (13-17 years of age)</u></p><p>The efficacy and safety of lamotrigine IR as add-on maintenance therapy to delay mood episodes in male and female children and adolescents (age 10-17 years) who had been diagnosed with bipolar I disorder and who had remitted or improved from a bipolar episode while treated with lamotrigine in combinations with concomitant antipsychotic or other mood-stabilising drugs.</p><p>&nbsp;</p><p>The result of the primary efficacy analysis (time to occurrence of a bipolar event &ndash; TOBE) did not reach statistical significance. Thus efficacy was not shown. In addition, safety results showed increased reporting of suicidal behaviours in lamotrigine treated patients the lamotrigine.</p><p><u>Study of the effect of lamotrigine on cardiac conduction</u></p><p>The effect of repeat doses of lamotrigine (up to 400 mg/day) on cardiac conduction, as assessed by 12-lead ECG. There was no clinically significant effect of lamotrigine on QT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Lamotrigine is rapidly and completely absorbed from the gut with no significant first-pass metabolism. Peak plasma concentrations occur approximately 2.5 hours after oral administration of lamotrigine. Time to maximum concentration is slightly delayed after food but the extent of absorption is unaffected. There is considerable inter-individual variation in steady state maximum concentrations but within an individual, concentrations rarely vary.</p><p><strong><u>Distribution</u></strong></p><p>Binding to plasma proteins is about 55%; it is very unlikely that displacement from plasma proteins would result in toxicity.</p><p>The volume of distribution is 0.92 to 1.22 L/kg.</p><p><strong><u>Biotransformation</u></strong></p><p>UDP-glucuronyl transferases have been identified as the enzymes responsible for metabolism of lamotrigine.</p><p>Lamotrigine induces its own metabolism to a modest extent depending on dose. However, there is no evidence that lamotrigine affects the pharmacokinetics of other AEDs and data suggest that interactions between lamotrigine and medicinal products metabolised by cytochrome P<sub>450</sub> enzymes are unlikely to occur.</p><p><strong><u>Elimination</u></strong></p><p>The apparent plasma clearance in healthy subjects is approximately 30 mL/min. Clearance of lamotrigine is primarily metabolic with subsequent elimination of glucuronide-conjugated material in urine. Less than 10% is excreted unchanged in the urine. Only about 2% of lamotrigine-related material is excreted in faeces. Clearance and half-life are independent of dose. The apparent plasma half-life in healthy subjects is estimated to be approximately 33 hours (range 14 to 103 hours). In Gilbert&#39;s Syndrome, mean apparent clearance was reduced by 32% compared with normal controls but the values are within the range for the general population.</p><p>The half-life of lamotrigine is greatly affected by concomitant medicinal products. Mean half-life is reduced to approximately 14 hours when given with glucuronidation-inducing medicinal products such as carbamazepine and phenytoin and is increased to a mean of approximately 70 hours when co-administered with valproate alone.</p><p><u>&nbsp;</u></p><p><u>Linearity</u></p><p>The pharmacokinetics of lamotrigine are linear up to 450 mg, the highest single dose tested.</p><p><u>Special patient populations</u></p><p><em><u>Children</u></em></p><p>Clearance adjusted for body weight is higher in children than in adults with the highest values in children under five years. The half-life of lamotrigine is generally shorter in children than in adults with a mean value of approximately 7 hours when given with enzyme-inducing medicinal products such as carbamazepine and phenytoin and increasing to mean values of 45 to 50 hours when co-administered with valproate alone.</p><p><em><u>Infants aged 2 to 26 months</u></em></p><p>The mean half-life was estimated at 23 hours in infants younger than 26 months on enzyme-inducing therapy, 136 hours when co-administered with valproate and 38 hours in subjects treated without enzyme inducers/inhibitors. The inter-individual variability for oral clearance was high in the group of paediatric patients of 2 to 26 months (47%). The predicted serum concentration levels in children of 2 to 26 months were in general in the same range as those in older children, though higher Cmax levels are likely to be observed in some children with a body weight below 10 kg.</p><p><em><u>Elderly</u></em></p><p>Results of a population pharmacokinetic analysis including both young and elderly patients with epilepsy, indicated that the clearance of lamotrigine did not change to a clinically relevant extent. The mean clearance in the elderly (0.39 mL/min/kg) lies within the range of the mean clearance.</p><p>For this patient population, initial doses of lamotrigine should be based on the patient&#39;s concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment.</p><p><em><u>Hepatic impairment</u></em></p><p>Escalation and maintenance doses should generally be reduced in patients with moderate or severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&Oslash;&nbsp; Calcium Carbonate.</p><p>&Oslash;&nbsp; Povidone.</p><p>&Oslash;&nbsp; Sodium Starch Glycolate.</p><p>&Oslash;&nbsp; Aluminum Magnesium Silicate.</p><p>&Oslash;&nbsp; Sodium Saccharrine.</p><p>&Oslash;&nbsp; Low-Substituted Hydroxypropyl Cellulose.</p><p>&Oslash;&nbsp; Black Current Flavor.</p><p>Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Don&rsquo;t store above 30 C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>SEIZET<sup>&reg;</sup></strong> Dispersible/Chewable Tablets are packed in PVC/PVDC, Aluminum blister then packed in cardboard cartons with a multifold leaflet in pack size of 30 Dispersible/Chewable Tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma-Saudi
King Abdulaziz road - Alrabea District
Grand Center 1st floor – Front of Kingdom Hospital
P.O Box 47315 Riyadh, 13456 Saudi Arabia
Phone: + 966112790122 Ext. 200
Fax: +966112471323
E-mail: Albaraa.bahhari@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December, 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>